mesenteric desmoid tumor developing on the site of an excised

3
[Rare Tumors 2010; 2:e33] [page 91] Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor Mohammad Khan, 1 George Bozas, 1 Justin Cooke, 2 Kevin Wedgwood, 3 Anthony Maraveyas 1 1 Academic Department of Oncology, Queen’s Cancer Centre, Castle Hill Hospital, Cottingham, UK; 2 Department of Pathology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 3 Department of Surgery, Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Hospital, Cottingham, UK Abstract We present a case of a rare and unusual occurrence of a desmoid tumor at the site of a resected gastrointestinal stromal tumor and mimicking a recurrence, with a brief discus- sion of the management of desmoid tumors. Introduction Desmoid tumors, also known as deep or aggressive fibromatoses, are rare with an annual incidence of two to four cases per mil- lion. 1 The term desmoid, coined by Muller in 1838, is derived from the Greek word desmos, which means tendon-like. 2 They represent low- grade mesenchymal neoplasms, originating from musculo-aponeurotic stromal elements. They do not metastasize but tend to exhibit a high degree of local infiltration and invasion, thus becoming lethal in some cases, depend- ing on their anatomical localization. 3 Desmoid tumor development has been associated with genetic predisposition in patients with familial adenomatous polyposis (FAP) 4 and previous trauma of the area. 5,6 Dysregulation of the Wnt signaling pathway, which is involved in the pathogenesis of FAP and also in the process of wound healing, may be a critical underlying molecular mechanism in FAP-associated cases and possibly in sporadic ones as well. 7 In one third of sporadic cases, chromosomal changes such as trisomy-20 or -8 have been identified. 8 An association with the female gender and pregnancy 9 suggests a pathogenetic role for estrogenic influence; nevertheless, relative data are observational. We report here a rare and unusual case of desmoid tumor developing at the site of a gastrointestinal stromal tumor (GIST) resec- tion. This created the impression of GIST recurrence. Surgical excision of the lesion was a difficult decision owing to the suspicion of metastatic disease. We present a discussion on the basis of this case for the management of both desmoid tumors and GIST. Case Report A 37-year-old IT engineer with an otherwise unremarkable medical history was admitted to the acute assessment unit with acute upper gastrointestinal bleeding. An ultrasound scan of the abdomen performed as part of the work- up for this condition revealed a large gastric mass and liver lesions consistent with metas- tases. Contrast-enhanced computed tomog- raphy (CT) of the abdomen showed a 15 cm exophytic mass originating from the gastric wall (Figure 1A) and four enhancing liver lesions of 19 mm maximum diameter (Figure 1C). Endoscopy revealed a single gastric fundal mass with a large ulcer that was biopsied. Histological diagnosis was of a GIST, staining positively for C-KIT and CD34 and with a high mitotic rate. PET imaging showed a markedly increased uptake in the gastric mass (SUV 15). The larger of the imaged liver lesions did not show any significant FDG uptake while the smaller lesions were not assessable. Treatment with imatinib mesylate (400 mg daily) was initiated, and the first assessment CT scan performed three months later showed a partial response of the gastric tumor (Figure 1B), according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. 10 In addition, the liver lesions were reduced in size uniformly. This treatment was continued and further scans over the next five months showed stable disease. Subsequent scans were done as magnetic resonance imaging (MRI) to assess the extent of the hepatic lesions, from which it was concluded that they were not metastatic in nature. In light of a good response to treatment the patient underwent a total abdominal gastrectomy. The procedure achieved excision of the tumor together with an intraoperatively detected omental second- ary lesion (Figures 1C). Pathological findings reported positive margins (microscopic-R1 resection) at the splenic and pancreatic aspects. Imatinib was continued postoperative- ly. Plans for surgical removal of the liver lesions were abandoned when the MRI scan of the liver revealed multiple nonspecific tiny lesions widespread throughout the liver parenchyma. The patient remained asymptomatic and well on imatinib treatment for another 11 months, when a repeat MRI scan of the abdomen revealed a new mesenteric mass 3 cm in diameter (Figure 1D), while the appear- ance of the liver lesions remained unchanged. A multidisciplinary team meeting decision was made to resect the lesion surgically. The excised lesion represented a firm nodular mass with a thin connective tissue capsule, measuring 6.0¥4.0¥4.5 cm (Figure 2). A mesenteric and an anterior abdominal wall nodule were also removed. Microscopically the larger mass appeared as a circumcised unen- capsulated tumor of varying cellularity. Toward the periphery it was composed of spindle cells with elongated nuclei and a small amount of pale eosinophilic cytoplasm arranged between broad sweeping fascicles (Figure 3A). No nuclear atypia was noted. Toward the center of the lesion there was pronounced keloidal colla- gen deposition (Figure 3B). The tumor showed weak staining for desmin and was negative for CD34 and C-KIT. The pattern was typical of an intra-abdominal desmoid tumor. The other two nodules turned out to be a mesenteric lymph node with sinus histiocytosis and a pseudo- cyst with no evidence of malignancy. The patient continued on imatinib (400 mg OD) treatment and follow-up MRI scans did not show any recurrence of the desmoid tumor over the next eight months. Discussion Desmoid tumors usually manifest as slow- growing, deep-seated, painless or slightly painful masses and can develop at virtually any anatomical site. 11 Typically three localizations are described: trunk/extremity, abdominal wall, and intra-abdominal region. Usually FAP-asso- ciated cases occur in the abdomen, while non- FAP-associated cases present in the shoulder or hip regions and in the extremities. 5 They can be multifocal on an extremity, but different anatomical regions rarely are affected in the same patient. Inside the abdomen they can Rare Tumors 2010; volume 2:e33 Correspondence: Mohammad Muneeb Khan, Queen’s Cancer Centre, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ, UK. E-mail: [email protected] Key words: mesenteric desmoid tumor, gastro- intestinal stromal tumor. Received for publication: 27 September 2009. Revision received: 23 March 2010. Accepted for publication: 25 March 2010. This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). ©Copyright M. Khan et al., 2010 Licensee PAGEPress, Italy Rare Tumors 2010; 2:e33 doi:10.4081/rt.2010.e33

Upload: dinhque

Post on 13-Jan-2017

222 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Mesenteric desmoid tumor developing on the site of an excised

[Rare Tumors 2010; 2:e33] [page 91]

Mesenteric desmoid tumordeveloping on the site of an excised gastrointestinalstromal tumorMohammad Khan,1 George Bozas,1Justin Cooke,2 Kevin Wedgwood,3Anthony Maraveyas1

1Academic Department of Oncology,Queen’s Cancer Centre, Castle HillHospital, Cottingham, UK;2Department of Pathology, Hull and EastYorkshire Hospitals NHS Trust, Hull, UK;3Department of Surgery, Hull and EastYorkshire Hospitals NHS Trust, Castle HillHospital, Cottingham, UK

Abstract

We present a case of a rare and unusualoccurrence of a desmoid tumor at the site of aresected gastrointestinal stromal tumor andmimicking a recurrence, with a brief discus-sion of the management of desmoid tumors.

Introduction

Desmoid tumors, also known as deep oraggressive fibromatoses, are rare with anannual incidence of two to four cases per mil-lion.1 The term desmoid, coined by Muller in1838, is derived from the Greek word desmos,which means tendon-like.2 They represent low-grade mesenchymal neoplasms, originatingfrom musculo-aponeurotic stromal elements.They do not metastasize but tend to exhibit ahigh degree of local infiltration and invasion,thus becoming lethal in some cases, depend-ing on their anatomical localization.3 Desmoidtumor development has been associated withgenetic predisposition in patients with familialadenomatous polyposis (FAP)4 and previoustrauma of the area.5,6 Dysregulation of the Wntsignaling pathway, which is involved in thepathogenesis of FAP and also in the process ofwound healing, may be a critical underlyingmolecular mechanism in FAP-associated casesand possibly in sporadic ones as well.7 In onethird of sporadic cases, chromosomal changessuch as trisomy-20 or -8 have been identified.8

An association with the female gender andpregnancy9 suggests a pathogenetic role forestrogenic influence; nevertheless, relativedata are observational. We report here a rare and unusual case of

desmoid tumor developing at the site of a gastrointestinal stromal tumor (GIST) resec-

tion. This created the impression of GISTrecurrence. Surgical excision of the lesion wasa difficult decision owing to the suspicion ofmetastatic disease. We present a discussion onthe basis of this case for the management ofboth desmoid tumors and GIST.

Case Report

A 37-year-old IT engineer with an otherwiseunremarkable medical history was admitted tothe acute assessment unit with acute uppergastrointestinal bleeding. An ultrasound scanof the abdomen performed as part of the work-up for this condition revealed a large gastricmass and liver lesions consistent with metas-tases. Contrast-enhanced computed tomog -raphy (CT) of the abdomen showed a 15 cmexophytic mass originating from the gastricwall (Figure 1A) and four enhancing liverlesions of 19 mm maximum diameter (Figure1C). Endoscopy revealed a single gastric fundalmass with a large ulcer that was biopsied.Histological diagnosis was of a GIST, stainingpositively for C-KIT and CD34 and with a highmitotic rate. PET imaging showed a markedlyincreased uptake in the gastric mass (SUV15). The larger of the imaged liver lesions didnot show any significant FDG uptake while thesmaller lesions were not assessable.Treatment with imatinib mesylate (400 mg

daily) was initiated, and the first assessmentCT scan performed three months later showeda partial response of the gastric tumor (Figure1B), according to the RECIST (ResponseEvaluation Criteria in Solid Tumors) criteria.10

In addition, the liver lesions were reduced insize uniformly. This treatment was continuedand further scans over the next five monthsshowed stable disease. Subsequent scans weredone as magnetic resonance imaging (MRI) toassess the extent of the hepatic lesions, fromwhich it was concluded that they were notmetastatic in nature. In light of a goodresponse to treatment the patient underwent atotal abdominal gastrectomy. The procedureachieved excision of the tumor together withan intraoperatively detected omental second-ary lesion (Figures 1C). Pathological findingsreported positive margins (microscopic-R1resection) at the splenic and pancreaticaspects. Imatinib was continued postoperative-ly. Plans for surgical removal of the liverlesions were abandoned when the MRI scan ofthe liver revealed multiple nonspecific tinylesions widespread throughout the liverparenchyma.The patient remained asymptomatic and

well on imatinib treatment for another 11months, when a repeat MRI scan of theabdomen revealed a new mesenteric mass 3cm in diameter (Figure 1D), while the appear-

ance of the liver lesions remained unchanged.A multidisciplinary team meeting decision wasmade to resect the lesion surgically. Theexcised lesion represented a firm nodularmass with a thin connective tissue capsule,measuring 6.0¥4.0¥4.5 cm (Figure 2). Amesenteric and an anterior abdominal wallnodule were also removed. Microscopically thelarger mass appeared as a circumcised unen-capsulated tumor of varying cellularity. Towardthe periphery it was composed of spindle cellswith elongated nuclei and a small amount ofpale eosinophilic cytoplasm arranged betweenbroad sweeping fascicles (Figure 3A). Nonuclear atypia was noted. Toward the center ofthe lesion there was pronounced keloidal colla-gen deposition (Figure 3B). The tumor showedweak staining for desmin and was negative forCD34 and C-KIT. The pattern was typical of anintra-abdominal desmoid tumor. The other twonodules turned out to be a mesenteric lymphnode with sinus histiocytosis and a pseudo-cyst with no evidence of malignancy. Thepatient continued on imatinib (400 mg OD)treatment and follow-up MRI scans did notshow any recurrence of the desmoid tumorover the next eight months.

Discussion

Desmoid tumors usually manifest as slow-growing, deep-seated, painless or slightlypainful masses and can develop at virtually anyanatomical site.11 Typically three localizationsare described: trunk/extremity, abdominal wall,and intra-abdominal region. Usually FAP-asso-ciated cases occur in the abdomen, while non-FAP-associated cases present in the shoulderor hip regions and in the extremities.5 Theycan be multifocal on an extremity, but differentanatomical regions rarely are affected in thesame patient. Inside the abdomen they can

Rare Tumors 2010; volume 2:e33

Correspondence: Mohammad Muneeb Khan,Queen’s Cancer Centre, Castle Hill Hospital,Castle Road, Cottingham, HU16 5JQ, UK.E-mail: [email protected]

Key words: mesenteric desmoid tumor, gastro -intestinal stromal tumor.

Received for publication: 27 September 2009.Revision received: 23 March 2010.Accepted for publication: 25 March 2010.

This work is licensed under a Creative CommonsAttribution 3.0 License (by-nc 3.0).

©Copyright M. Khan et al., 2010Licensee PAGEPress, ItalyRare Tumors 2010; 2:e33doi:10.4081/rt.2010.e33

Page 2: Mesenteric desmoid tumor developing on the site of an excised

[page 92] [Rare Tumors 2010; 2:e33]

cause changes in bowel habits, pain, obstruc-tion, ischemia, rectal bleeding, or a dysfunc-tional anastomosis, and are a significant causeof mortality for FAP patients. Non-intra-abdom-inal desmoids have a better prognosis.7,12

Complete surgical resection remains thecornerstone of management of desmoidtumors, while unresectable or residual diseasecan be treated with radical radiotherapy.11

Depending on tumor size, type of treatment,and negative margins post-resection, recur-rences occur in up to 45% of treated adultcases, usually within three years from diagno-sis.13 Systemic treatments with NSAIDs, anti -

estrogens or androgens, chemotherapy (dox-orubicin-based, methotrexate, vinblastine,vinorelbine), and lately imatinib have beenused for unresectable or relapsed desmoids,often resulting in long-lasting responses.14 Inselected asymptomatic patients, a period ofwatchful waiting is recommended.15

Prior trauma is identified in 30% of patientswho develop desmoid tumors, and is typicallyabdominal surgery for FAP.4 In addition, spor -adic cases of intra-abdominal desmoid tumorshave been observed in sites of previous abdom-inal surgery.12,16,17 Our literature search yieldedone previous report of a desmoid tumor arisingin the site of a previously excised GIST.18 GISTsand desmoid tumors share a common stromalorigin but are diverse histologically, genetical-ly, and biologically. Nevertheless, surgical trau-ma at the GIST excision site may predispose tothe development of the desmoid tumor. Anaccurate diagnosis is possible only after surgi-cal removal and pathological exam ination, asthere are no typical imaging findings to sug-gest a desmoid tumor. Excluding recurrence ofthe GIST was crucial for the further manage-ment of our patient; he remained on imatinibfor the metastatic GIST; therefore he contin-ued to benefit from first-line treatment andremains progression-free after eight months.

References

1. Reitamo JJ, Häyry P, Nykyri E, Saxén E.The desmoid tumor. Incidence, sex, ageand anatomical distribution in the Finnishpopulation. Am J Clin Pathol 1982;77:665-73.

2. Müller J. Veber den Feinern Bau und dieFormen der Krankhaftlichen Geschwulste.Berlin: G Reimer, p 80, 1838.

3. Schlemmer M. Desmoid tumors and deepfibromatoses. Hematol Oncol Clin NorthAm 2005;19:565-71.

4. Soravia C, Berk T, McLeod RS, Cohen Z.Desmoid disease in patients with familialadenomatous polyposis. Dis Colon Rectum2000;43:363-9.

5. De Cian F, Delay E, Rudigoz RC, et al.Desmoid tumor arising in a Cesarean sec-tion scar during pregnancy: monitoringand management. Gynecol Oncol 1999;75:145-8.

6. Penna C, Tiret E, Parc R, et al. Operationand abdominal desmoid tumors in familialadenomatous polyposis. Surg GynecolObstet 1993;177:263-8.

7. Kotiligam D, Lazar AJ, Pollock RE, Lev D.Desmoid tumor: a disease opportune formolecular insights. Histol Histopathol2008;23:117-26.

8. Dei Tos AP, Dal Cin P. The role of cyto -

Case Report

Figure 1. A contrast-enhanced computed tomography scan of the abdomen showing: a15-cm exophytic mass originating from the gastric wall (arrow) (A); and four enhancingliver lesions of maximal diameter of 19 mm (C). A three-month follow-up abdominal CTscan (B) demonstrated a partial response to treatment of the gastric tumor (arrow). Arepeat MRI scan of the abdomen after 11 months revealed a secondary mesenteric omen-tal mass, 3 cm in diameter (D).

Figure 2. Macroscopic view of the second-ary mesenteric lesion, showing it as a firmnodular mass with a thin connective tissuecapsule, measuring 6.0¥4.0¥4.5 cm.

Figure 3. A histological section of the larg-er mass illustrating: (A) toward the periph-ery of the tumor, spindle cells with elongat-ed nuclei and a small amount of paleeosinophilic cytoplasm, and (B) pro-nounced keloidal collagen depositiontoward the center of the lesion. No nuclearatypia was noted. (Hematoxylin and eosinstain; magnification 100X).

A

B

Page 3: Mesenteric desmoid tumor developing on the site of an excised

[Rare Tumors 2010; 2:e33] [page 93]

genetics in the classification of soft tissuetumours. Virchows Arch 1997;431:83-94.

9. Gansar GF, Markowitz IP, Cerise EJ. Thirtyyears of experience with desmoid tumors atCharity Hospital. Am Surg 1987;53:318-9.

10. Therasse P, Arbuck SG, Eisenhauer EA, etal. New guidelines to evaluate theresponse to treatment in solid tumors. JNatl Cancer Inst 2000;92:205-16.

11. Ballo MT, Zagars GZ, Pollack A, et al.Desmoid Tumor: Prognostic Factors andOutcome After Surgery, RadiationTherapy, or Combined Surgery andRadiation Therapy. J Clin Oncol 1999;17:158-67.

12. Enzinger FM, Weiss SW. Soft TissueTumors. 3rd ed. St Louis: Mosby-YearbookInc., p 201, 1995.

13. Nuyttens JJ, Rust PF, Thomas CR Jr, et al.Surgery versus radiation therapy forpatients with aggressive fibromatosis ordesmoid tumors: a comparative review of22 articles. Cancer 2000;88:1517-23.

14. Patel SR, Benjamin RS. Desmoid TumorsRespond to Chemotherapy: Defying theDogma in Oncology. J Clin Oncol 2006;24:11-2.

15. De Bree E, Keus R, Melissas J, et al.Desmoid tumours: Need for an individual-ized approach. Expert Rev Anticancer Ther

2009;9:525-35.16. Kersting S, Herbst H, Senninger N,

Mittelkötter U. Intra-abdominal fibromato-sis after ap pendectomy as cause for ileus.Zentralbl Chir 2004;129:317-20.

17. Moudouni SM, Tazi Mokha K, Nouri M, etal. Desmoid tumor of the mesentery sec-ondary to colectomy. An exceptional causeof ureteric obstruction. Ann Urol 1999;33:424-7.

18. Vendrell J-F, Mazars R, Funakoshi N, et al.Desmoid tumor subsequent to resection ofa gastrointestinal stromal tumor. Eur JRadiol 2008;65:9-11.

Case Report